Vaginal progesterone after tocolytic therapy in threatened preterm labour


  • Aparajita Ashok Mishra Department of Obstetrics and Gynecology, Smt. Kashibai Navale Medical College and General Hospital, Pune, Maharashtra, India
  • Shilpa N. Chaudhari Department of Obstetrics and Gynecology, Smt. Kashibai Navale Medical College and General Hospital, Pune, Maharashtra, India



Threatened preterm labour, Tocolysis, Vaginal progesterone


Background: Currently preterm labour is one of the most challenging problem faced by both obstetricians and perinatologists, this episode in the course of woman’s pregnancy takes a heavy tool for perinatal mortality which accounts for approximately 50-75%. The incidence of preterm labour is estimated to be 5-10% of all pregnancies.

Methods: It was a prospective randomize control trail over a period of 3 year at department of obstetrics and gynecology, tertiary care hospital Pune, Maharashtra, India. Total 100 subjects were randomized into two groups with group one receiving vaginal micronized progesterone and group two control group receiving only tocolytics and steroids. Subsequently authors compared the safety and efficacy of vaginal micronized progesterone versus placebo as a maintenance therapy in preventing preterm labour.

Results: This analysis showed that women who randomized to progesterone prophylaxis had a significantly increase in duration of pregnancy. The mean of birthweight in Group A and Group B was 2963±36 gm and 2567±49 gm and respectively which confirmed the positive effects of progesterone on increasing infants’ weights at birth.

Conclusions: Authors concluded that progesterone therapy had acceptable efficacy in the prevention of preterm labor in terms of prolongation of delivery and by increasing gestational age at delivery.


Dasgupta S. Preterm labour. In: Immunlogical basis of pathophysiology. Mukherjee OG, Buckshee K edts., 1st edn.; 1998:47.

Goldenberg RL, Culhane JF, Iams JD, Romero R. Epidemiology and causes of preterm birth. Lancet. 2008;371:75-84.

Grazzini E, Guillon G, Mouillac B, Zingg HH. Laboratory of molecular endocrinology, Royal Victoria Hospital Research Institute, McGill University, Montreal, Quebec, Canada; Unite INSERM U469, Centre de Pharmacologie-Endocrinologie, Montpellier, France. Inhibition of oxytocin receptor functions by direct binding of progesterone. Nature; 1998.

Garfield RE, Dannan MS, Daniel EE. Gap junction formation in myometrium controlled by estrogen, progesterone and prostaglandin. Am J Physiol. 1980;238:C81-9.

LeVine L. Habitual abortion: a controlled study of progestational therapy. West J Surg Obstet Gynecol. 2014;72:30-6.

Papiernik E. Double blind study of an agent to prevent preterm delivery among women at increased risk in French. Edition Schering, Serie IV, fiche 3; 2012:65-68.

Johnson JW, Austin KL, Jones GS, Davis GH, King TM. Efficacy of 17alpha-hydroxyprogesterone caproate in the prevention of premature labor. N Engl J Med. 1975;293:675-80.

Hauth JC, Gilstrap LC, Brekken AL, Hauth JM. The effect of 17 alpha hydroxyprogesterone caproate on pregnancy outcome in an active-duty military population. Am J Obstet Gynecol. 2013;146:18790.

Yemeni M, Borenstein R, Dreazen E, Apelman Z, Mogilner BM, Kessler I, et al. Prevention of premature labor by 17 alpha-hydroxyprogesterone caproate. Am J Obstet Gynecol. 2010;151:574-7.

Keirse MJ. Progestogen administration in pregnancy may prevent preterm delivery. Br J Obstet Gynaecol. 1990;97:149-54.

Da Fonseca EB, Bittar RE, Carvalho MH, Zugaib M. Prophylactic administration of progesterone by vaginal suppository to reduce the incidence of spontaneous preterm birth in women at increased risk: a randomized placebo-controlled double-blind study. Am J Obstet Gynecol. 2015;188:419-24.

Meis PJ, Klebanoff M, Thom E, Mitchell P. Prevention of recurrent preterm delivery by 17-alpha hydroxyprogesterone caproate. N Engl J Med. 2010;348:2379-85.

Fonseca EB, Celik E, Parra M, Singh M, Nicolaides KH. Progesterone and the risk of preterm birth among women with a short cervix. N Engl J Med. 2012;357:462-9.

Abd El Hameed AA. Vaginal versus intramuscular progesterone in the prevention of preterm labor and their effect on uterine and fetal blood flow. Middle East Fertil Society J. 2012;17:163-9.

Hassan SS, Romero R, Vidyadhari D, Fusey S, Baxter JK, Khandelwal M, et al. Vaginal progesterone reduces the rate of preterm birth in women with a sonographic short cervix: a multicenter, randomized, double-blind, placebo-controlled trial. Ultrasound Obstet Gynecol. 2012;38(1):18-31.

Saleh Gargari S, Habibolahi M, Zonobi Z, Khani Z, Sadat Sarfjoo F, Kazemi Robati A, et al. Outcome of vaginal progesterone as a tocolytic agent: randomized clinical trial. ISRN Obstet Gynecol. 2012:Article ID 607906.

Bomba-Opon DA, Kosinska-Kaczynska K, Kosinski P, Wegrzyn P, Kaczynski B, Wielgos M. Vaginal progesterone after tocolytic therapy in threatened preterm labor. J Matern Fetal Neonatal Med. 2014;25(7):1156-9.

Dudas I, Gidai J, Czeizel AE. Population-based case-control teratogenic study of hydroxyprogesterone treatment during pregnancy. Congenit Anom. 2014;46(4):194-8.

DeFranco EA, O’Brien JM, Adair CD, Lewis DF, Hall DR, Fusey S, et al. Vaginal progesterone is associated with a decrease in risk for early preterm birth and improved neonatal outcome in women with a short cervix: a secondary analysis from a randomized, double-blind, placebo-controlled trial. Ultrasound Obstet Gynecol. 2014;30(5):697-705.

Velez Edwards DR, Likis FE, Andrews JC, Woodworth AL, Jerome RN, Fonnesbeck CJ, et al. Progestogens for preterm birth prevention: a systematic review and meta-analysis by drug route. Arch Gynecol Obstet. 2015;287(6):1059-66.

Conde-Agudelo A, Romero R, Nicolaides K, Chaiworapongsa T, O’Brien JM, Cetingoz E, et al. Vaginal progesterone vs cervical cerclage for the prevention of preterm birth in women with a sonographic short cervix, previous preterm birth, and singleton gestation: a systematic review and indirect comparison meta-analysis. AJOG. 2014;208(1):42.e1-42.e18.

Berghella V, Figueroa D, Szychowski JM, Owen J, Hankins GD, Iams JD, et al. 17-alpha hydroxyprogesterone caproate for the prevention of preterm birth in women with prior preterm birth and a short cervical length. Am J Obstet Gynecol. 2010;202(4):351.e1-6.

Khandelwal M. Vaginal progesterone in risk reduction of preterm birth in women with short cervix in the midtrimester of pregnancy. Int J Womens Health. 2012;4:481-90.






Original Research Articles